State Street

KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on:

Thursday, February 15, 2024

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common stock in lieu of KalVista common stock to certain investors.

Key Points:

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share and (ii) pre-funded warrants to purchase 3,483,688 shares of common stock in lieu of KalVista common stock to certain investors.
The gross proceeds to KalVista from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by KalVista, are expected to be $160.1 million.
In addition, KalVista has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
All of the shares of common stock and pre-funded warrants are being offered by KalVista.

KalVista Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Retrieved on:

Wednesday, February 14, 2024

Pharmaceutical, Health, Clinical Trials, Attention, Jefferies Group, Prospectus, Capital market, Suite, Telephone, Cantor, Sale, Montgomery Street, Form, State Street, SVB Securities, Madison Avenue, KALV, Security (finance)

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering.

Key Points:

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) announced today that it intends to offer and sell shares of its common stock and pre-funded warrants to purchase shares of common stock in lieu of KalVista common stock to certain investors in an underwritten public offering.
In addition, KalVista intends to grant the underwriters a 30-day option to purchase an additional 15% of the securities offered in the public offering at the public offering price less underwriting discounts and commissions.
All of the shares and pre-funded warrants will be offered and sold by KalVista.
Jefferies, Leerink Partners, Stifel and Cantor are acting as the joint book-running managers for the proposed offering.

Helix Acquisition Corp. II Announces Closing of $184 Million Initial Public Offering, Including the Full Exercise of the Underwriter's Option to Purchase Additional Shares

Retrieved on:

Wednesday, February 14, 2024

Banking, Professional Services, Finance, Acquisition, Prospectus, Telephone, Sale, Exercise, ATTN:, IPO, State Street, SVB Securities, Trust, Partner, Security (finance)

The Company is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Key Points:

The Company is a special purpose acquisition company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
While the Company may pursue an initial business combination target in any business or industry, it intends to focus on opportunities in healthcare or healthcare-related industries.
The Company’s Class A ordinary shares began trading on The Nasdaq Capital Market under the ticker symbol “HLXB” on February 9, 2024.
A total of $184,000,000 comprised of the net proceeds from the IPO and simultaneous private placement were placed in trust.

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Retrieved on:

Wednesday, February 14, 2024

Attention, Prospectus, Larimar, Telephone, Floor, Sale, Form, State Street, SVB Securities, Therapy, Madison Avenue, Guggenheim, Security (finance), Guggenheim Partners, Research

BALA CYNWYD, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 17,162,472 shares of its common stock at a price to the public of $8.74 per share, the closing price of its common stock on February 13, 2024, for gross proceeds of approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses.

Key Points:

BALA CYNWYD, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 17,162,472 shares of its common stock at a price to the public of $8.74 per share, the closing price of its common stock on February 13, 2024, for gross proceeds of approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses.
In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 2,574,370 shares of its common stock at the public offering price, less underwriting discounts and commissions.
All shares of common stock are being offered by Larimar.
The offering is expected to close on or about February 16, 2024, subject to the satisfaction of customary closing conditions.

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Retrieved on:

Wednesday, February 14, 2024

The proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $175.3 million.

Key Points:

The proceeds to the Company from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by the Company, are expected to be approximately $175.3 million.
In addition, the Company has granted the underwriters a 30-day option to purchase up to an additional 1,383,750 Ordinary Shares at the public offering price, less underwriting discounts and commissions.
The Offering is expected to close on or about February 16, 2024, subject to satisfaction of customary closing conditions.
Jefferies, Leerink Partners, Piper Sandler, and RBC Capital Markets are acting as joint book-running managers for the Offering.

Immunome Announces Pricing of Public Offering of Common Stock

Retrieved on:

Wednesday, February 14, 2024

Biotechnology, Pharmaceutical, Health, Oncology, Attention, Lexington Avenue, Prospectus, Telephone, File, Sale, Form, State Street, Broadridge Financial Solutions, SVB Securities, Madison Avenue, Guggenheim, S-3, Guggenheim Partners, Security (finance)

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $20.00 per share.

Key Points:

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $20.00 per share.
The gross proceeds to Immunome from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be $200.0 million.
In addition, Immunome has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the offering.

Azitra, Inc. Announces Pricing of Public Offering

Retrieved on:

Wednesday, February 14, 2024

Biotechnology, Pharmaceutical, Health, Other Health, ThinkEquity, Prospectus, Sale, Form, State Street, Form S-1, Security (finance), Research

Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of an underwritten public offering of 16,667,000 shares of common stock.

Key Points:

Azitra, Inc. (NYSE American: AZTR) (“Company”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the pricing of an underwritten public offering of 16,667,000 shares of common stock.
Each share of common stock is being sold at a public offering price of $0.30 per share for gross proceeds of approximately $5 million, before deducting underwriting discounts and offering expenses.
In addition, Azitra has granted the underwriters a 45-day option to purchase up to an additional 2,500,000 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount.
The offering is expected to close on February 16, 2024, subject to satisfaction of customary closing conditions.

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Retrieved on:

Tuesday, February 13, 2024

Attention, Prospectus, Larimar, Telephone, Floor, Sale, Form, State Street, SVB Securities, Therapy, Madison Avenue, Guggenheim, Security (finance), Guggenheim Partners, Research

In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions.

Key Points:

In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions.
All shares of common stock and pre-funded warrants in the proposed offering are to be sold by Larimar.
The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering.
Leerink Partners, Citigroup and Guggenheim Securities are acting as joint bookrunning managers for the proposed offering.

Immunome Announces Proposed Public Offering of Common Stock

Retrieved on:

Tuesday, February 13, 2024

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its common stock.

Key Points:

Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced its plans to commence an underwritten public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its common stock.
In connection with the proposed offering, Immunome expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.
There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities are acting as joint book-running managers for the proposed offering.

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

Retrieved on:

Tuesday, February 13, 2024

Attention, Jefferies Group, Prospectus, Telephone, Cardiovascular disease, RBC Capital Markets, Sale, Equity capital markets, Form, Nicollet Mall, Risk, NAMS, State Street, SVB Securities, Madison Avenue, Patient, Common stock, Vesey Street

NAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of the Company’s ordinary shares, with a nominal value of €0.12 per share (“Ordinary Shares,”) and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” such offering, the “Offering”).

Key Points:

NAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of the Company’s ordinary shares, with a nominal value of €0.12 per share (“Ordinary Shares,”) and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” such offering, the “Offering”).
All Ordinary Shares and Pre-Funded Warrants to be sold in the proposed Offering will be sold by the Company.
In addition, the Company expects to grant the underwriters a 30-day option to purchase a number of additional shares not to exceed 15% of the securities sold in the proposed Offering.
Jefferies, Leerink Partners, Piper Sandler, and RBC Capital Markets are acting as joint book-running managers for the proposed Offering.